Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PBT2

            Therapeutic Area: Infections and Infectious Diseases Product Name: PBT2

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Alterity Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership December 21, 2020

            Details:

            The licensed technology combines Alterity’s PBT2 and other zinc ionophores with commonly used antibiotics to treat infections caused by multidrug resistant bacteria. This is an opportunity for Alterity to further leverage its investment in PBT2.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IMM-124E

            Therapeutic Area: Infections and Infectious Diseases Product Name: Travelan

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Monash University

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement December 15, 2020

            Details:

            A New Research Services Agreement has been executed with Monash University to advance the SARS-CoV-2 findings and to further research and identify the inhibitory substance/s in Immuron’s marketed products (IMM-124E).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Recce 327

            Therapeutic Area: Infections and Infectious Diseases Product Name: Recce 327

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 11, 2020

            Details:

            RECCE® 327 showed encouraging inhibition and is advancing to Stage 1b (confirmatory in-vitro testing and a cytotoxicity assessment), underway in near weeks.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): INNA-051

            Therapeutic Area: Infections and Infectious Diseases Product Name: INNA-051

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 28, 2020

            Details:

            The novel product, INNA-051, being developed by Australian biotech company, Ena Respiratory, reduced viral replication by up to 96 percent in a gold-standard animal study led by Public Health England.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Recce 327

            Therapeutic Area: Infections and Infectious Diseases Product Name: Recce 327

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Australian Government Department of Industry, Science, Energy and Resources

            Deal Size: $0.02 million Upfront Cash: Undisclosed

            Deal Type: Funding September 01, 2020

            Details:

            The grant will be directed towards project costs associated with assessing RECCE® 327 in the SARS-CoV-2 Antiviral Screening Program and is subject to performance based milestones.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): RECCE 435

            Therapeutic Area: Infections and Infectious Diseases Product Name: RECCE 435

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 05, 2020

            Details:

            New RECCE® 435 oral showed dose-dependent and efficacy against Helicobacter pylori (H. pylori) bacteria isolated from a patient with a duodenal ulcer compared to control vehicle in independent study model in rats.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IMM-124E

            Therapeutic Area: Infections and Infectious Diseases Product Name: IMM-124E

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 23, 2020

            Details:

            IMM-124E, the technology platform used to manufacture the company’s over-the-counter gastrointestinal & digestive health immune supplements Travelan® and Protectyn® has demonstrated neutralizing activity against SARS-CoV-2 in laboratory studies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AT-301

            Therapeutic Area: Infections and Infectious Diseases Product Name: AT-301

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Atossa Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration July 22, 2020

            Details:

            The study is a double-blinded, randomized, and placebo-controlled safety study of AT-301 nasal spray in 32 healthy adult subjects divided into two study groups.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Recce 327

            Therapeutic Area: Infections and Infectious Diseases Product Name: Recce 327

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: CSIRO

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement July 08, 2020

            Details:

            RECCE® 327 and New RECCE® 529 compounds were selected for their unique mechanisms of action against hyper-mutation, as indicated on bacteria and viruses (respectively).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Pixatimod

            Therapeutic Area: Infections and Infectious Diseases Product Name: PG545

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 26, 2020

            Details:

            Zucero’s clinical-stage drug candidate pixatimod demonstrates potent antiviral activity against the COVID-19 virus in laboratory studies.

            PharmaCompass